Jardiance Dosage/Direction for Use

Type 2 diabetes mellitus: The recommended starting dose of JARDIANCE is 10 mg once daily. In patients tolerating empagliflozin 10 mg once daily and requiring additional glycaemic control, the dose can be increased to 25 mg once daily.
Combination therapy: When JARDIANCE is used in combination with a sulfonylurea or with insulin, a lower dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see Interactions and Adverse Reactions).
Heart failure: The recommended dose is 10 mg empagliflozin once daily.
JARDIANCE can be taken with or without food.
Patients with renal impairment: Assess renal function prior to initiation of empagliflozin and periodically thereafter. (See Table 18.)

Click on icon to see table/diagram/image

For treatment of heart failure in patients with or without type 2 diabetes mellitus, empagliflozin 10 mg may be initiated or continued down to an eGFR of 20 mL/min/1.73m² or CrCl of 20 mL/min.
Patients with hepatic impairment: No dose adjustment is required for patients with hepatic impairment. Empagliflozin exposure is increased in patients with severe hepatic impairment. Therapeutic experience in patients with severe hepatic impairment is limited and therefore not recommended for use in this population.
Elderly Patients: No dosage adjustment is recommended based on age. Therapeutic experience in patients aged 85 years and older is limited. Initiation of empagliflozin therapy in this population is not recommended (see Precautions). Patients age 75 years and older should be prescribed with caution (see Precautions).
Paediatric population: Safety and effectiveness of JARDIANCE in children under 18 years of age have not been established.